COMP <GO>
BIO vs RVTY // PIOTROSKI F-SCORE QUALITY
Bio-Rad Laboratories Inc. (NYSE) VS. Revvity Inc. (NYSE) • 15-METRIC TALLY: BIO 5
— RVTY 7
■ METRIC PARITY
LAST: $384.40 (-0.19%) • MKT CAP: $10.28B
piotroski-score
7/9
LAST: $165.78 (+0.27%) • MKT CAP: $18.50B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. RVTY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | RVTY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.50% | 3.10% | -2.60 | RVTY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 48.2x | +12.20 | RVTY | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 2.75% | +0.89 | BIO | /fcf-yield <GO> |
| Operating Margin | 1.80% | 12.50% | -10.70 | RVTY | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 8.40% | +21.00 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 3.70% | -3.00 | RVTY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.18% | -0.18 | RVTY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 3.37 | +0.22 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.0 | 64.5 | -5.50 | RVTY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.95 | +0.09 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 71.3x | -58.70 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $18.50B | -$8.22B | RVTY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | RVTY REV | BIO GROSS % | RVTY GROSS % | BIO FCF | RVTY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $2.86B | 51.9% | — | $374.6M | $509.4M |
| FY 2024 | $2.57B | $2.76B | 53.7% | — | $289.6M | $541.7M |
| FY 2023 | $2.67B | $2.75B | — | — | $254.7M | -$32.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
RVTY // BETA 0.95